Melanoma Risk-Reduction Among Patients and Family Members
|ClinicalTrials.gov Identifier: NCT00510302|
Recruitment Status : Active, not recruiting
First Posted : August 2, 2007
Last Update Posted : July 14, 2017
- To conduct semi-structured interviews with melanoma patients and family members to collect descriptive information on their UVR exposure, UVR exposure-reduction practices, melanoma early detection practices, knowledge, psychosocial variables related to melanoma risk-reduction (e.g., self-efficacy, norms, and expectations), and experiences surrounding the diagnosis of melanoma in the family. Melanoma patients and family members with children will be asked about the UVR exposure and UVR exposure-reduction practices of their children, and parental practices to reduce UVR exposure among children.
- To develop behavioral and attitudinal questionnaires based on data collected during semi-structured interviews, and evaluate the appropriateness of these questionnaires using cognitive interviewing techniques.
- To develop tailored messages aimed at promoting strategies to reduce UVR exposure (e.g., wearing protective clothing, minimizing midday UVR exposure, minimizing duration of UVR exposure, using shade and sunscreen, avoiding sun lamps, and avoiding intentional tanning) and improving adherence to surveillance and screening guidelines. Messages will be developed to correspond to responses to questionnaire items.
- To assess tailored messages for their relevance, appropriateness, attractiveness and appeal, credibility, and perceived behavioral impact among melanoma patients and their family members.
|Condition or disease||Intervention/treatment|
|Melanoma||Behavioral: Questionnaire Behavioral: Interview|
Participants in Part 1 of the study will be asked to be interviewed about topics related to melanoma risk-reduction, including opinions, attitudes, beliefs, and practices related to ultraviolet radiation exposure, melanoma prevention, and melanoma detection.
Participants in Part 2 of the study will be asked to complete a written questionnaire on melanoma risk-reduction and then be interviewed to obtain feedback on how the questionnaire may be refined.
Participants in Part 3 of the study will be asked to be interviewed by telephone. Participants then will receive educational material in the form of a newsletter tailored to their interview responses. Participants then will be asked to be interviewed to obtain feedback for refining the educational material. In each part of the study, the patient/family member will receive a letter describing the study and the Consent Statement for Questionnaire and Interview Studies.
Prior to the start of the interview, the Consent Statement will be read to the patient/family member. Patients/family members may or may not choose to have the interview tape-recorded. Participants may stop the interview or questionnaire at any time and may refuse to answer any questions. At any time, the patient/family member may refuse to have the interview tape-recorded. There is no treatment associated with this study.
|Study Type :||Observational|
|Estimated Enrollment :||170 participants|
|Official Title:||Melanoma Risk-Reduction Practices Among Melanoma Patients and Their Family Members|
|Study Start Date :||November 2002|
|Estimated Primary Completion Date :||November 2018|
|Estimated Study Completion Date :||November 2018|
Patients with melanoma, their spouses/partners, and first-degree relatives (FDRs).
Questionnaire regarding melanoma risk-reduction.
Other Name: SurveyBehavioral: Interview
Interview via telephone about topics related to melanoma risk-reduction.
- Information on ultraviolet radiation (UVR-E) reduction + early detection practices of melanoma patients and family members [ Time Frame: 8 Years ]
- Development of questionnaires + tailored intervention messages on melanoma risk-reduction in a high-risk population [ Time Frame: 8 years ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00510302
|United States, Texas|
|University of Texas MD Anderson Cancer Center|
|Houston, Texas, United States, 77030|
|Principal Investigator:||Susan Peterson, PhD||M.D. Anderson Cancer Center|